After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer
pharmaphorum
DECEMBER 23, 2022
Here, Richard Staines reports on phase I/II data unveiled at the American Society of Hematology conference that supports further clinical development of inobrodib in multiple myeloma and other blood cancers. Richard Staines made a move into PR with Optimum after more than twenty years as a journalist. About the author.
52 
Let's personalize your content